BridgeMD
New treatment option for Chronic Coronary Syndrome
Official title Optimal Evaluation to Reduce Cardiovascular Imaging Testing
ClinicalTrials.gov ID: NCT05640752
What this study is testing
- What it's testing
- In daily clinical routine, the evaluation of new-onset and stable chest pain (SCP) suggestive of chronic coronary syndrome (CCS) remains a challenge for physicians. Although coronary computed tomography angiography (CCTA) seems to be the first-line cardiac imaging testing (CIT) according to the recommendations from current guidelines, the optimal diagnostic strategy to identify low risk patients who may derive minimal benefit from further CIT is the cornerstone of clinical management for SCP.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 30 to 90
You may be able to join if
- SCP or equivalenta suggestive of CCS and clinically stability
- No history of CAD (prior myocardial infarction, CR or any CAD documented by previous CIT)
- Age ≥30 years
- Willing and able to provide informed consent
You likely can't join if
- Prior CIT within 1 year prior to randomization
- Clinically instability (e.g. cardiogenic shock, ACS, severe arrhythmias or NYHA III or IV heart failure)
- Non-sinus rhythm
- Concomitant participation in another clinical trial
- Complex structural heart disease
- Non-cardiac illness with life expectancy \< 2 years
See the full eligibility criteria
- SCP or equivalenta suggestive of CCS and clinically stability
- No history of CAD (prior myocardial infarction, CR or any CAD documented by previous CIT)
- Age ≥30 years
- Willing and able to provide informed consent
- Prior CIT within 1 year prior to randomization
- Clinically instability (e.g. cardiogenic shock, ACS, severe arrhythmias or NYHA III or IV heart failure)
- Non-sinus rhythm
- Concomitant participation in another clinical trial
- Complex structural heart disease
- Non-cardiac illness with life expectancy \< 2 years
- Allergy to iodinated contrast agent
- Estimated glomerular filtration rate\<60 ml/min/1.73m2 within 90 days
- Body mass index \>35kg/m2
- Expressing a clear preference for undergoing CIT or not
- Pregnancy
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
- Lanfang, Hebei, China
- Tianjin, Tianjin Municipality, China
- Tianjin, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 30 years to 90 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China; Lanfang, Hebei, China; Tianjin, Tianjin Municipality, China; Tianjin, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.